{
    "id": 17005,
    "fullName": "POLE mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "POLE mutant indicates an unspecified mutation in the POLE gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 5426,
        "geneSymbol": "POLE",
        "terms": [
            "POLE",
            "CRCS12",
            "FILS",
            "IMAGEI",
            "POLE1"
        ]
    },
    "variant": "mutant",
    "createDate": "01/21/2016",
    "updateDate": "02/13/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 18496,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immune checkpoint inhibitor (ICI) treatment, including CTLA4, PD-1, and PD-L1-targeting antibodies, resulted in prolonged overall survival (34 vs 18 months, p=0.004) in patients with advanced solid tumors harboring POLE or POLD1 mutations compared to wild-type patients, and POLE/POLD1 mutation served as a predictor of response to ICI (p=0.047, HR=1.41) independent of MSI-H status (PMID: 31415061).",
            "molecularProfile": {
                "id": 17290,
                "profileName": "POLE mutant"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16286,
                    "pubMedId": 31415061,
                    "title": "Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31415061"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18494,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immune checkpoint inhibitor (ICI) treatment, including CTLA4, PD-1, and PD-L1-targeting antibodies, resulted in prolonged overall survival (34 vs 18 months, p=0.004) in patients with advanced solid tumors harboring POLE or POLD1 mutations compared to wild-type patients, and POLE/POLD1 mutation served as a predictor of response to ICI (p=0.047, HR=1.41) independent of MSI-H status (PMID: 31415061).",
            "molecularProfile": {
                "id": 17290,
                "profileName": "POLE mutant"
            },
            "therapy": {
                "id": 5489,
                "therapyName": "unspecified CTLA4 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16286,
                    "pubMedId": 31415061,
                    "title": "Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31415061"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18495,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, immune checkpoint inhibitor (ICI) treatment, including CTLA4, PD-1, and PD-L1-targeting antibodies, resulted in prolonged overall survival (34 vs 18 months, p=0.004) in patients with advanced solid tumors harboring POLE or POLD1 mutations compared to wild-type patients, and POLE/POLD1 mutation served as a predictor of response to ICI (p=0.047, HR=1.41) independent of MSI-H status (PMID: 31415061).",
            "molecularProfile": {
                "id": 17290,
                "profileName": "POLE mutant"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16286,
                    "pubMedId": 31415061,
                    "title": "Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31415061"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16015,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and responses were associated with higher levels of CD8+ tumor infitrating lymphocytes (TILs), PD-1 expressing CD8+ TILs, and tumor-infiltrating T-cells with a Th1 phenotype (CD4+ Tbet+) (PMID: 29998005).",
            "molecularProfile": {
                "id": 31363,
                "profileName": "PDCD1 pos POLE mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14093,
                    "pubMedId": 29998005,
                    "title": "Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29998005"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16017,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and PD-L1 (CD274) expression was not associated with response (PMID: 29998005).",
            "molecularProfile": {
                "id": 31369,
                "profileName": "CD274 pos POLE mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14093,
                    "pubMedId": 29998005,
                    "title": "Immune profiling of microsatellite instability-high and polymerase \u03b5 (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29998005"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17290,
            "profileName": "POLE mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31363,
            "profileName": "PDCD1 pos POLE mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31369,
            "profileName": "CD274 pos POLE mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}